IBIO Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of -255.85%. iBio, Inc.'s return on equity of -88.23% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

iBio, Inc. has a consensus price target of $4.72, signalling upside risk potential of 112.61%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -53.04%. Given that iBio, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe iBio, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

iBio, Inc. has a beta of 1.135, which suggesting that the stock is 13.459% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. iBio, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are $100K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. iBio, Inc.'s net income of -$5.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 98.12x versus 3.52x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Minerva Neurosciences, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of --. iBio, Inc.'s return on equity of -88.23% beat Minerva Neurosciences, Inc.'s return on equity of --.

iBio, Inc. has a consensus price target of $4.72, signalling upside risk potential of 112.61%. On the other hand Minerva Neurosciences, Inc. has an analysts' consensus of $4.50 which suggests that it could grow by 15.39%. Given that iBio, Inc. has higher upside potential than Minerva Neurosciences, Inc., analysts believe iBio, Inc. is more attractive than Minerva Neurosciences, Inc..

iBio, Inc. has a beta of 1.135, which suggesting that the stock is 13.459% more volatile than S&P 500. In comparison Minerva Neurosciences, Inc. has a beta of -0.396, suggesting its less volatile than the S&P 500 by 139.575%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Minerva Neurosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Minerva Neurosciences, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are $100K, which are larger than Minerva Neurosciences, Inc. quarterly revenues of --. iBio, Inc.'s net income of -$5.7M is lower than Minerva Neurosciences, Inc.'s net income of -$2.7M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Minerva Neurosciences, Inc.'s PE ratio is 2.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 98.12x versus -- for Minerva Neurosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -5720% compared to iBio, Inc.'s net margin of --. iBio, Inc.'s return on equity of -88.23% beat Palatin Technologies's return on equity of --.

iBio, Inc. has a consensus price target of $4.72, signalling upside risk potential of 112.61%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than iBio, Inc., analysts believe Palatin Technologies is more attractive than iBio, Inc..

iBio, Inc. has a beta of 1.135, which suggesting that the stock is 13.459% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are $100K, which are larger than Palatin Technologies quarterly revenues of --. iBio, Inc.'s net income of -$5.7M is higher than Palatin Technologies's net income of --. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 98.12x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of --. iBio, Inc.'s return on equity of -88.23% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

iBio, Inc. has a consensus price target of $4.72, signalling upside risk potential of 112.61%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3039.01%. Given that Theriva Biologics, Inc. has higher upside potential than iBio, Inc., analysts believe Theriva Biologics, Inc. is more attractive than iBio, Inc..

iBio, Inc. has a beta of 1.135, which suggesting that the stock is 13.459% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are $100K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. iBio, Inc.'s net income of -$5.7M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 98.12x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.